Infinium Pharmachem has announced the resumption of business operations at its manufacturing facility located at Plot 38-39 GIDC, Sojitra. This development follows the acceptance of a revocation application by the Gujarat Pollution Control Board (GPCB), which subsequently issued an order revoking the earlier closure direction.

Revocation Details

The GPCB issued the Revocation Order under Section 33(A) of the Water (Prevention and Control of Pollution) Act, 1974. The company confirmed receipt of this order on May 20, 2026. As per the communication, the company has ensured compliance with the conditions stipulated in the revocation order to facilitate the restart of operations.

Operational Resumption

Consequent to the regulatory approval, Infinium Pharmachem stated that it will commence regular manufacturing and operational activities at the Sojitra plant starting May 20, 2026. The management is undertaking necessary steps to ensure a smooth transition back to full production while adhering to all applicable statutory and regulatory requirements.

Key Regulatory Information

The following table outlines the specific details regarding the regulatory order and its impact on the company's operations:

Infinium Pharmachem has announced the commencement of operations at its new manufacturing plant specifically designed for producing contrast media raw materials. This strategic expansion represents a significant milestone in the company's growth trajectory within the pharmaceutical sector.

New Manufacturing Facility Details

The newly operational plant focuses on the production of raw materials used in contrast media, which are essential components in medical imaging procedures. The facility marks the company's commitment to expanding its manufacturing capabilities in specialized pharmaceutical segments.

Revenue Projections

The company has set ambitious targets for the new facility, projecting annual revenue of approximately ₹100.00 crore from this manufacturing plant. This revenue expectation indicates the company's confidence in market demand for contrast media raw materials and its ability to capture a significant share of this specialized market segment.

Strategic Significance

The launch of this dedicated manufacturing plant demonstrates Infinium Pharmachem's strategic focus on expanding its presence in the contrast media segment. Contrast media raw materials represent a specialized niche within the pharmaceutical industry, requiring specific manufacturing capabilities and regulatory compliance. By establishing dedicated production facilities for these materials, the company positions itself to serve the growing demand in the medical imaging sector.